WO2006102177A3 - Biomarkers for efficacy of aliskiren as a hypertensive agent - Google Patents

Biomarkers for efficacy of aliskiren as a hypertensive agent Download PDF

Info

Publication number
WO2006102177A3
WO2006102177A3 PCT/US2006/009913 US2006009913W WO2006102177A3 WO 2006102177 A3 WO2006102177 A3 WO 2006102177A3 US 2006009913 W US2006009913 W US 2006009913W WO 2006102177 A3 WO2006102177 A3 WO 2006102177A3
Authority
WO
WIPO (PCT)
Prior art keywords
aliskiren
angiotensin
efficacy
polymorphisms
gene
Prior art date
Application number
PCT/US2006/009913
Other languages
French (fr)
Other versions
WO2006102177A2 (en
Inventor
Jessie Gu
Joanne Meyer
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Jessie Gu
Joanne Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Jessie Gu, Joanne Meyer filed Critical Novartis Ag
Priority to CA002600525A priority Critical patent/CA2600525A1/en
Priority to EP06748451A priority patent/EP1863939A2/en
Priority to US11/909,202 priority patent/US20100240760A1/en
Priority to BRPI0609702-2A priority patent/BRPI0609702A2/en
Priority to AU2006227283A priority patent/AU2006227283B2/en
Priority to MX2007011697A priority patent/MX2007011697A/en
Priority to JP2008503059A priority patent/JP2008538549A/en
Publication of WO2006102177A2 publication Critical patent/WO2006102177A2/en
Publication of WO2006102177A3 publication Critical patent/WO2006102177A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty-eight polymorphisms were examined in twelve genes from the renin-angiotensin-aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant associations were seen between one polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the angiotensin II type 2 receptor (AGTR2) gene, and clinical parameters of mean sitting diastolic and systolic blood pressure decrease. These effects were not found with irbesartan and placebo treatment, but instead were specific to aliskiren treatment.
PCT/US2006/009913 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent WO2006102177A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002600525A CA2600525A1 (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent
EP06748451A EP1863939A2 (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent
US11/909,202 US20100240760A1 (en) 2005-03-22 2006-03-20 Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent
BRPI0609702-2A BRPI0609702A2 (en) 2005-03-22 2006-03-20 biomarkers for the efficacy of aliskiren as a hypertensive agent
AU2006227283A AU2006227283B2 (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent
MX2007011697A MX2007011697A (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent.
JP2008503059A JP2008538549A (en) 2005-03-22 2006-03-20 Biomarkers on the effectiveness of aliskiren as a hypertensive agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66424805P 2005-03-22 2005-03-22
US60/664,248 2005-03-22
US74240106P 2006-02-06 2006-02-06
US60/742,401 2006-02-06

Publications (2)

Publication Number Publication Date
WO2006102177A2 WO2006102177A2 (en) 2006-09-28
WO2006102177A3 true WO2006102177A3 (en) 2007-05-10

Family

ID=37024459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/009913 WO2006102177A2 (en) 2005-03-22 2006-03-20 Biomarkers for efficacy of aliskiren as a hypertensive agent

Country Status (8)

Country Link
US (1) US20100240760A1 (en)
JP (1) JP2008538549A (en)
KR (1) KR20080005926A (en)
AU (1) AU2006227283B2 (en)
BR (1) BRPI0609702A2 (en)
CA (1) CA2600525A1 (en)
MX (1) MX2007011697A (en)
WO (1) WO2006102177A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227283B2 (en) * 2005-03-22 2010-07-01 Novartis Ag Biomarkers for efficacy of aliskiren as a hypertensive agent
AU2008309059A1 (en) * 2007-09-28 2009-04-09 Novartis Ag Pharmaceutical combination of Aliskiren and Valsartan
CN108660205A (en) * 2018-07-04 2018-10-16 刘城 A kind of diabetes genetic risk assessment kit and its utilization
CN111024960B (en) * 2019-12-27 2023-02-17 广州阳普医疗科技股份有限公司 Additive for detecting hypertension blood sample, kit and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008457A1 (en) * 1987-04-30 1988-11-03 Biotechnology Research Partners, Ltd. Hypertension-related blood tests useful as genetic markers
WO2000022166A2 (en) * 1998-10-14 2000-04-20 Pyrosequencing Ab Genes for assessing cardiovascular status and compositions for use thereof
WO2006082570A1 (en) * 2005-02-02 2006-08-10 Royal College Of Surgeons In Ireland Pharmacogenomics of blood pressure lowering agents
WO2006102177A2 (en) * 2005-03-22 2006-09-28 Novartis Ag Biomarkers for efficacy of aliskiren as a hypertensive agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0310084A (en) * 2002-05-17 2005-02-15 Novartis Ag A pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008457A1 (en) * 1987-04-30 1988-11-03 Biotechnology Research Partners, Ltd. Hypertension-related blood tests useful as genetic markers
WO2000022166A2 (en) * 1998-10-14 2000-04-20 Pyrosequencing Ab Genes for assessing cardiovascular status and compositions for use thereof
WO2006082570A1 (en) * 2005-02-02 2006-08-10 Royal College Of Surgeons In Ireland Pharmacogenomics of blood pressure lowering agents
WO2006102177A2 (en) * 2005-03-22 2006-09-28 Novartis Ag Biomarkers for efficacy of aliskiren as a hypertensive agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARNETT DONNA K ET AL: "Pharmacogenetics of antihypertensive treatment", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 62, no. 3, July 2004 (2004-07-01), pages 191 - 199, XP002340073, ISSN: 0272-4391 *
GRADMAN A H ET AL: "Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients", AMERICAN JOURNAL OF HYPERTENSION, ELSEVIER, vol. 17, no. 5, May 2004 (2004-05-01), pages S108, XP004575685, ISSN: 0895-7061 *
KURLAND L ET AL: "ANGIOTENSINOGEN GENE POLYMORPHISMS: RELATIONSHIP TO BLOOD PRESSURE RESPONSE TO ANTIHYPERTENSIVE TREATMENT", AMERICAN JOURNAL OF HYPERTENSION, ELSEVIER, vol. 17, no. 1, January 2004 (2004-01-01), pages 8 - 13, XP002340072, ISSN: 0895-7061 *
TIRET L ET AL: "EVIDENCE FROM COMBINED SEGREGATION AND LINKAGE ANALYSIS THAT A VARIANT OF THE ANGIOTENSIN I-CONVERTING ENZYME ACE GENE CONTROLS PLASMA ACE LEVELS", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 51, no. 1, 1992, pages 197 - 205, XP002421964, ISSN: 0002-9297 *

Also Published As

Publication number Publication date
AU2006227283A1 (en) 2006-09-28
BRPI0609702A2 (en) 2010-04-20
JP2008538549A (en) 2008-10-30
AU2006227283B2 (en) 2010-07-01
KR20080005926A (en) 2008-01-15
US20100240760A1 (en) 2010-09-23
MX2007011697A (en) 2007-11-16
CA2600525A1 (en) 2006-09-28
WO2006102177A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2007045197A3 (en) Expression profiles for predicting septic conditions
Krishnan et al. Association of angiotensin converting enzyme gene insertion/deletion polymorphism with essential hypertension in south Indian population
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
WO2009073345A3 (en) Assay for detecting genetic abnormalities in genomic nucleic acids
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2008083331A3 (en) Diagnostic and therapeutic target for autoimmune diseases and uses thereof
WO2009055773A3 (en) Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2009026422A3 (en) Treatment of central nervous system disorders
EP2367007A3 (en) Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
SI1730315T1 (en) Polymorphisms in nod2/card15 gene
WO2005077462A3 (en) Cd70 inhibition for the treatment and prevention of inflammatory bowel disease
WO2007110623A3 (en) Screening method
WO2006102177A3 (en) Biomarkers for efficacy of aliskiren as a hypertensive agent
Ortlepp et al. Variants of the CYP11B2 gene predict response to therapy with candesartan
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
Ferreira de Oliveira et al. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea andcreatinine variations in patients with dementia due to Alzheimer disease
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
NO20073636L (en) Compositions and Methods to Treat Mental Disorders
WO2006046270A3 (en) Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof
Currie et al. Investigation of ACE, ACE2 and AGTR1 genes for association with nephropathy in Type 1 diabetes mellitus
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2009140679A3 (en) Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680009605.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006748451

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6872/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2600525

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11909202

Country of ref document: US

Ref document number: 2006227283

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008503059

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011697

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006227283

Country of ref document: AU

Date of ref document: 20060320

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077024124

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007138882

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06748451

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0609702

Country of ref document: BR

Kind code of ref document: A2